Molecular targets for antifibrotic therapy in liver disease: Using magic bullets for crossfire rather than a one-sided shotgun attack

Gut

Volumn 63, Issue 7, 2014, Pages 1039-1041

  Hellerbrand, Claus ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE 1;

FIBROGENESIS; HUMAN; INSULIN RESISTANCE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER FIBROSIS; MYOFIBROBLAST; NONALCOHOLIC FATTY LIVER; NONHUMAN; NOTE; PRIORITY JOURNAL; STELLATE CELL;

HEPATIC FIBROSIS; HEPATIC STELLATE CELL;

ANIMALS; HEPATIC STELLATE CELLS; HUMANS; LIVER CIRRHOSIS; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 8;

EID: 84902266505     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2013-305908     Document Type: Note

References (10)

1. Weston CR, Davis RJ. The JNK signal transduction pathway. Curr Opin Cell Biol 2007;19:142-9. (Pubitemid 46386399)
2. Seki E, Brenner DA, Karin M. A liver full of JNK: signaling in regulation of cell function and disease pathogenesis, and clinical approaches. Gastroenterology 2012;143:307-20.
3. Liu X, Xu J, Brenner DA, et al. Reversibility of Liver Fibrosis and Inactivation of Fibrogenic Myofibroblasts. Curr Pathobiol Rep 2013;1:209-14.
4. Kocabayoglu P, Friedman SL. Cellular basis of hepatic fibrosis and its role in inflammation and cancer. Front Biosci (Schol Ed) 2013;5: 217-30.
5. Zhao G, Hatting M, Nevzorova YA, et al. Jnk1 in murine Hepatic Stellate Cells is a crucial mediator of liver fibrogenesis. Gut 2014;63: 1159-72.
6. Kluwe J, Pradere JP, Gwak GY, et al. Modulation of hepatic fibrosis by c-Jun-N-terminal kinase inhibition. Gastroenterology 2010;138:347-59.
7. Das M, Garlick DS, Greiner DL, et al. The role of JNK in the development of hepatocellular carcinoma. Genes Dev 2011;25:634-45.
8. Czaja MJ. JNK regulation of hepatic manifestations of the metabolic syndrome. Trends Endocrinol Metab 2010;21:707-13.
9. Luedde T, Schwabe RF. NF-κB in the liver-linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2011;8:108-18.
10. Poelstra K, Beljaars L, Melgert BN. Cell-specific delivery of biologicals: problems, pitfalls and possibilities of antifibrotic compounds in the liver. Drug Discov Today Published Online First: 31 May 2013. pii: S 1359-6446(13)00159-1. doi:10.1016/j. drudis.2013.05.013.